(IN BRIEF) Roche and Nurix Therapeutics have entered into an exclusive global licensing and collaboration agreement to co-develop and co-commercialise bexobrutideg, also known as NX-5948, an investigational oral BTK degrader with potential applications across malignant haematology, immunology and neurology. The … Read the full press release
Posted in Business, European Union, Financial, Government, Healthcare, Industrial, Investment, Law, Management, Marketing, Pharma & Biotech, Science, Switzerland, Technology
Tagged Arthur T Sands, B-cell malignancies, bexobrutideg, brain-penetrant therapy, Bruton’s tyrosine kinase, BTK, BTK degrader, BTK inhibitors, chronic lymphocytic leukaemia, chronic spontaneous urticaria, CLL, co-commercialisation, co-development, CSU, Hart-Scott-Rodino Antitrust Improvements Act, immunology, Immunology and Neurology Pipeline with Global Bexobrutideg Collaboration, kinase activity, Levi Garraway, licensing agreement, malignant haematology, MS, multiple sclerosis, Neurology, NHL, Non-Hodgkin lymphoma, Nurix Therapeutics, NX-5948, oncology pipeline, oral therapy, Phase 3 clinical trial, relapsed or refractory B-cell malignancies, Roche, Roche and Nurix Announce Up to USD 2.3 Billion Collaboration to Develop and Commercialise Bexobrutideg, Roche and Nurix Therapeutics Partner on Potential Best-in-Class Targeted Protein Degrader for B-Cell Malignancies, Roche oncology, Roche Strengthens Oncology, scaffolding function, Switzerland, targeted protein degradation, targeted protein degrader, treatment resistance, United States, USD 2.3 billion deal value, USD 700 million upfront payment
(IN BRIEF) Roche presented new data at ECTRIMS 2025 confirming that OCREVUS provides sustained protection against disability progression and maintains a consistent safety profile across multiple MS populations, including adults with advanced PPMS, children with RRMS, and women who are … Read the full press release
Posted in Healthcare, Management, Marketing, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged BTK inhibitor, disability progression, ECTRIMS 2025, fenebrutinib, FENhance, FENopta, FENtrepid, infant immunity, Levi Garraway, MINORE, MS, multiple sclerosis, neurofilament light chain, OCARINA II, ocrelizumab, OCREVUS, OPERETTA, ORATORIO-HAND, paediatric MS, PPMS, pregnancy outcomes, RMS, Roche, Roche presents late-breaking MS data including OCREVUS impact in pregnancy and two-year fenebrutinib Phase II outcomes, Roche showcases new OCREVUS and fenebrutinib data at ECTRIMS 2025 highlighting long-term efficacy and safety in MS, RRMS, SOPRANINO, Stephen L Hauser
Further strengthens core R&D areas of autoimmune and allergic diseases Provides full control of brain-penetrant BTK inhibitor SAR442168 in multiple sclerosis (MS), making commercialization more efficient and eliminating future royalty payments Allows expansion of SAR442168 development program into other central … Read the full press release
Posted in Business, France, Healthcare, Investment, News, Pharma & Biotech
Tagged acquisition, allergic diseases, Arnaud Delepine, Ashleigh Koss, autoimmune diseases, biopharmaceutical, BofA Securities, Bruton tyrosine kinase, BTK inhibitor, BTK inhibitor ‘168, Centerview Partners LLC, Christopher Chai, commercialization, Cooley LLP, Eva Schaefer-Jansen, Evercore, Fara Berkowitz, Felix Lauscher, Gotshal & Manges LLP, John Reed M.D. Ph.D., Martin Babler, MS, multiple sclerosis, Nicolas Kressmann, pathophysiology, Paul Hudson, Paul Laland, Pharmaceutical, Principia, Principia Biopharma, PRN473 Topical, rilzabrutinib, Sanofi, SAR442168, Suzanne Greco, Weil, Yvonne Naughton
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?